Could a nerve drug boost GIST treatment? early trial begins.
NCT ID NCT07171203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests adding fampridine to standard imatinib (Gleevec) in 18 adults with a specific type of GIST tumor. Participants take the drugs for at least 2 months before surgery to find the safest dose and see if the combination shrinks tumors. The goal is to improve treatment for this rare stomach cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of California, San Diego
RECRUITINGLa Jolla, California, 92093, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST